Volume 19, Number 4—April 2013
CME ACTIVITY - Research
Serotype IV and Invasive Group B Streptococcus Disease in Neonates, Minnesota, USA, 2000–20101
Table 2
Serotype distribution of invasive GBS isolates for cultures collected from infants, Minnesota, USA, January 2000–December 2010*
CPS type | No. (%) patients† |
||
---|---|---|---|
Early onset | Late onset | Total | |
Ia | 79 (30.7) | 57 (29.7) | 136 (30.3) |
Ib | 25 (9.7) | 12 (6.2) | 37 (8.2) |
II | 43 (16.7) | 5 (2.6) | 48 (10.7) |
III | 57 (22.2) | 95 (49.5) | 152 (33.9) |
IV | 8 (3.1) | 4 (2.1) | 12 (2.7) |
V | 39 (15.2) | 18 (9.4) | 57 (12.7) |
VII | 2 (0.8) | 0 (0.0) | 2 (0.4) |
Nontypeable |
4 (1.6) |
1 (0.5) |
5 (1.1) |
Total | 257 (100.0) | 192 (100.0) | 449 (100.0) |
*GBS, group B Streptococcus; CPS, capsular polysaccharide serotype.
†Early-onset, patient age birth–6 days; late-onset, patient age 7–180 days.
1This work was presented in part at the XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases, September 4–8, 2011, Palermo, Italy.